Home
Issues
Aim & Scope
Open Access
Editorial Board
Indexing
Why publish with us
Contact us
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Data Policies
Publication Ethics and Publication Malpractice Statement
EDITORIAL
Pneumococcal vaccination in adults: New perspectives for old problems
1
Assistant Professor in Pneumonology, Pneumonology Department, Aristotle University of Thessaloniki “G. Papanikolaou” Hospital, Εxohi, Thessaloniki
Corresponding author
Ioannis P. Kioumis
Pneumonology Department, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, 570 10 Exohi, Thessaloniki
Pneumonology Department, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, 570 10 Exohi, Thessaloniki
Pneumon 2012;25(3):265-267
REFERENCES (22)
1.
Centers for Disease Control and Prevention. Pneumococcal disease. In: Atkinson W, Wolfe C, Hamborsky J, McIntyre L, eds. The Pink Book. Epidemiology and Prevention of Vaccine Preventable Diseases. 12th ed. May 2012.
2.
Brown JS. Geography and the aetiology of community-acquired pneumonia. Respirology 2009;14:1068-71.
3.
Musher DM, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990;161:728-35.
4.
Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest 2008;133:767-74.
5.
Rodriguez-Barradas MC, Groover JE, Lacke CE, et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis 1996;173:1347-53.
6.
Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J.
8.
Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: Does it really work? Resp Med 2011;105:1776-83.
9.
Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomized and placebo controlled trial. BMJ 2010;340c1004.
10.
Huss A, Scott P, Stuck A, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180:48- 58.
11.
Gaillat J. Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases? Exp Rev Resp Med 2009;3:585-96.
12.
Elston JW, Santaniello-Newton A, Meigh JA, et al. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002-2009. Epidemiol Infect 2012;140(7):1252-66.
13.
Vila-Corcoles A, Ochoa-Gondar O, Rodringuez-Blanco T, et al. Clinical effectiveness of pneumococcal vaccination against acute myocardial infaction and stroke in people over 60 years: the CARAMIS study, one-year follow-up. BMC Public Health 2012;12:222.
14.
Pletz MW, Maus U, Hohlfeld JM, Lode H, Welte T. Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance. Dtsch Med Wochenschr 2008;133:358-62.
15.
Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004;10(8): 811-3.
16.
Scott D, Ruckle J, Dar M, Baker S, Kondoh H, Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int 2008;50:295-9.
17.
Dransfield MT, Nahm MH, Han MK, et al. COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:499-505.
18.
CDC: Morbidity and Mortality Weekly Report (MMWR, 2012;61:394-5): License of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. JAMA 2012;308(7): 663-4.
19.
Smith KJ, Wateska AR, Nowalk AR, et al. Cost-effectiveness of adult vaccination using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012;307(8):804-12.
20.
Lu PJ, Nuorti JP. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009. Am J Epidemiol 2012;175(8):827-37.
21.
Gilchrist SA, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach to policy makers. Am J Public Health 2012;102(4):596-605.
22.
Smith JG, Metzger NL. Evaluation of pneumococcal vaccination rates after vaccine protocol changes and nurse education in a tertiary care teaching. J Mag Care Pharm 2011;17(9):701-08.
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
